Notable Labs

Personalized combination therapies for cancer patients.

News and Press

Stanford, Notable Labs and Tempus collaborate on personalized medicine research for blood cancer

MedCity News • April 15, 2019

Researchers at Stanford took blood samples from patients and sent them to Chicago-based Tempus for genomic sequencing of the person’s cancer. Another sample was sent to Notable, which used its AI-based automated laboratory system to test hundreds of potential drug treatments against the disease and provided treatment recommendations based on that analysis. Stanford clinicians then used this data (alongside the clinical features of the patient) to create a report with individualized recommendations that could inform future treatment.

Peninsula biotech's nonprofit deal spotlights unique attack on cancer in kids

San Francisco Business Times • Jan. 22, 2019

The partnership between for-profit Notable Labs and nonprofit Cures Within Reach could bring a childhood cancer treatment — a combination discovered by Foster City's Notable Labs of a generic drug and a natural product — to market faster and cheaper.

Show all News and Press (4 more)

Blog Posts

One company’s failed drug is this company’s ‘jewel’

May 4, 2022

Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer

January 6, 2022

Prediction of clinical response to venetoclax plus decitabine in AML using a 7-day ex vivo assay

December 16, 2021

Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib as a Potential Novel Drug Combination for Pediatric AML

December 16, 2021
Show all Blog Posts (52 more)